For biopharmaceutical, medical device and diagnostic
manufacturers, navigating market access and reimbursement in the
inpatient hospital setting is a challenge in the Medicare program,
where most technologies are bundled into an existing payment rate.
This bundled payment methodology means that providers often lack
incentives to adopt new medical technologies not already reflected
in their costs. Since 2001, the Centers for Medicare & Medicaid
Services have offered manufacturers of new, groundbreaking
technologies the ability to apply for a New Technology Add-on
Payment (NTAP) designation for their drug, device or diagnostic
that will provide hospitals with extra payments when they use the
product for the 2-3 year period after market entry of product.
These add-on payments are often critical in a hospital's
decision to adopt new technologies.
Foley Hoag and The Moran Company, an HMA Company, hosted a webinar
dissecting the upcoming NTAP application process in 2023 and the
frequently asked questions surrounding this time limited program.
Our panelists, who have helped dozens of early-stage and mature
life sciences companies apply for and receive NTAP designation for
their novel medical technologies, discussed:
- Assessing whether or not your technology qualifies for NTAP
- Why some technologies succeed – and others don't – during the application process
- The dos and don'ts of engaging with CMS on your application
- Recent changes to the NTAP program, including navigating the new MEARIS application process
Download the presentation materials here.
Speakers:
- Ross Margulies, Partner, Healthcare, Foley Hoag
- Clare Mamerow, Principal, The Moran Company, an HMA Company
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
